RCS - Fusion Antibodies - Mammalian Display video

Fusion AntibodiesAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK0994La&default-theme=true

RNS Number : 0994L  Fusion Antibodies PLC  11 December 2025

REACH - Non-regulatory announcement*

 

11 December 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Mammalian Display video

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces that ahead of the commercial launch of the OptiMAL(®)
Human Antibody Discovery platform at the Antibody Engineering and Technology
conference in San Diego on 15 December 2025,  Fusion has prepared a short
video of Dr Richard Buick, CSO, explaining some of the features, science and
technology behind the Company's Mammalian Display technology. The technology
has been combined with Fusion's Opti-library to create the OptiMAL(®)
library. OptiMAL® is intended to be used to discover novel human antibodies
against any target. The mammalian display platform library design and method
is protected by US patent US12378696. The Mammalian Display technology can
also be used with other antibody libraries.

 

The video can be viewed on the Investor Hub section of Fusion's website at,
https://investorhub.fusionantibodies.com/s/7ea305
(https://investorhub.fusionantibodies.com/s/7ea305) .

 

Other Mammalian Display technologies are available and have been summarised in
the scientific literature e.g. Slavny P, Hegde M, Doerner A, Parthiban K,
McCafferty J, Zielonka S and Hoet R (2024) Advancements in mammalian display
technology for therapeutic antibody development and beyond: current landscape,
challenges, and future prospects. Front. Immunol. 15:1469329. doi:
10.3389/fimmu.2024.1469329.

 

Fusion Antibodies has compared its own Mammalian Display technology to the
competitor platforms in the review article and identified several superior
advantages. The most significant are its transduction efficiency of over 70%
and its ability to support very large libraries, exceeding 10⁹ variants.
These are summarised in the table below:

 

 

 Technology              OptiMAL(®)   Retrocyte Display  Other Lentiviral mammalian display  Transposase-mediated integration  Nuclease-directed integration  Recombinase-mediated integration
 Integration Efficiency  >70%         <5%                0.5-5%                              6-7.5%                            0.5-5%                         1.7%
 Reported library sizes  >10(9)       10(6)-10(8)        10(6)                               10(6)                             10(6)-10(8)                    10(6)-10(8)

 

If shareholders or prospective investors have further queries regarding the
Mammalian Display platform, please submit questions you may have regarding
this update using the facility provided.

 

Investor Presentation and Q&A: OptiMAL(®) Launch

 

Adrian Kinkaid, CEO of Fusion will provide a pre-recorded presentation and
Q&A session on the OptiMAL® launch from the Antibody Engineering &
Therapeutics Conference via the Company's Investor Hub on Tuesday, 16 December
2025, at 16:00 GMT.

 

The presentation is open to all existing and potential shareholders. Questions
are encouraged and can be pre-submitted via the webinar page.

 

Register and submit your questions
here: https://investorhub.fusionantibodies.com/webinars/mPqXOr-optimal-r-launch-investor-q-a
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Finvestorhub.fusionantibodies.com%2Fwebinars%2FmPqXOr-optimal-r-launch-investor-q-a&data=05%7C02%7C%7C496780f05fb64ccb6d5e08de380b957e%7Cb9c541d1c5cd4cf18b4e49d0b1ad9021%7C0%7C0%7C639009819894239162%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=QtQLtwnjv8sqKfyVf5GAZ2IvmCBy7jtgDpEhLHj4uhY%3D&reserved=0)

 

No material new information will be included in the presentation or Q&A.

 

Fusion Antibodies wants to keep its investors up to date with developments in
the Company technology and offerings. We have therefore created a space on the
Investor Hub which in contains an increasing number of videos providing more
information which may be of interest to investors. This can be found here,
https://investorhub.fusionantibodies.com/s/1b6535
(https://investorhub.fusionantibodies.com/s/1b6535) .

 

Enquiries:

 

 Investor questions on this announcement
 We encourage all investors to share questions on this announcement via our      Investor hub (https://investorhub.fusionantibodies.com/)
 investor hub

 Fusion Antibodies plc                                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                             Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

*About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain.  Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATMBBTMTJBTAA



            Copyright 2019 Regulatory News Service, all rights reserved